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A series of bis-naphthoquinone derivatives prepared by condensation of aryl aldehydes with lawsone were
tested for antiparasitic activities against Toxoplasma gondii and Trypanosoma brucei parasites. Monofluorophenyl
derivative 1a, 3,4-difluorophenyl analog 1c and furyl compound 1l exhibited significant activity against T. gondii
cells and appear to be new promising drug candidates against this parasite. The 3,4,5-trifluorophenyl derivative
1g and the isovanillyl derivative 1j displayed selective activity against Leishmania major amastigotes.
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Introduction
Parasitic diseases still represent an enormous world-
wide medical challenge.[1] Neglected tropical diseases
(NTDs) pose a particularly great danger both for local
people and travelers in many tropical and subtropical
countries.[2] Due to the climate change, further regions
of the world will likely be affected by these parasitic
diseases in the future.[2] There are only a few drugs
available against NTDs because big pharma is reluc-
tant to develop new and more potent drugs against
diseases that mainly poor people suffer from.[3] Vice
versa, poor people affected by NTDs are in want of
affordable drugs, which could, however, arise from
tapping into natural resources. Many natural product
derived drug candidates, active against various NTDs,
have emerged.[3] In addition, natural products con-
stitute sustainable, cheap materials.
Lawsone, for instance, is a natural 2-hydroxy-1,4-
naphthoquinone isolated from the Henna plant (Law-
sonia inermis) which is being applied for the manage-
ment of skin diseases in South Asia as a component of
the local Ayurveda and Unani folk medicine.[4,5] Law-
sone (2-hydroxy-1,4-naphthoquinone) is also a useful
starting material for the preparation of various related
quinones with proven bioactivity such as lapachol or
atovaquone.[4,5] Arylmethylene-substituted bis-naphtho-
quinone derivatives have been reported to exhibit only
moderate activities against human cancer cells which
makes them interesting candidates for the design of
selective antiparasitic drugs.[6] Indeed, a small series of
substituted bis-2-hydroxy-1,4-naphthoquinones includ-
ing 1a (Figure 1) was obtained with distinct activity
against Leishmania parasites.[7] Herein, we report on
expanded series of such new derivatives (e.g., fluoroar-
enes, vanillins, furans) with optimized activity and
selectivity against various parasites including Toxoplas-
ma gondii, Trypanosoma brucei and Leishmania.
Results and Discussion
The known compounds 1a and 1b and the new
analogs 1c–1l were obtained as solids from the one-
pot condensation reaction of two equivalents of 2-
hydroxy-1,4-naphthoquinone (lawsone) with the corre-
sponding aryl aldehyde and a catalytic amount of β-
alanine in warm acetic acid (Scheme 1).[7,8] The struc-
tures of the target compounds 1a–1l are shown in
Figure 1.
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The antiparasitic activity of the compounds 1a–1l
was initially tested against Toxoplasma gondii and
Trypanosoma brucei parasites and compared with the
toxicity against normal kidney epithelial Vero cells
(Table 1). The best performing compounds 1a and 1c
exhibited good and similar activities against T. gondii
cells with 1c showing a better selectivity for T. gondii
cells over Vero cells. Like 1a, the pentafluorophenyl
derivative 1h was more toxic to normal Vero cells than
to T. gondii cells. Atovaquone, which is commonly
applied for the treatment of toxoplasmosis, was used
as positive control and displayed the highest activity
and selectivity.[9] However, the toxicity of the most bis-
naphthoquinones (except for 1a and 1h) to Vero cells
was distinctly lower when compared with atovaquone.
In contrast to this varied spectrum of activities against
T. gondii, all compounds, except 1a and 1i which
displayed low double-digit IC50 values, were virtually
inactive against T. b. brucei cells. Pentamidine, an
approved drug for the treatment of sleeping sickness,
was applied as positive control with activity in the
nano-molar concentration range.[10]
The compounds 1a–1l were also tested against
Leishmania major promastigotes and amastigotes in
comparison to normal Vero cells (Table 2). Compounds
1a and 1h showed similar moderate activities against
the promastigotes (EC50=35.0 μM for 1a and 35.5 μM
for 1h). Compounds 1c and 1f were most active
against the amastigotes (EC50=23.7 μM for 1c and
22.6 μM for 1f) and more active than the known
compound 1a. However, these compounds showed
only poor selectivity. In contrast to that, compounds
1g and 1j displayed only slightly weaker activities than
1c and 1f against the amastigotes (EC50=34.1 μM for
1g and 37.9 μM for 1j) but reasonable selectivity when
compared with their effects on Vero cells (SI=4.18 for
1g and more than 2.64 for 1j). The activity of the
known compound 1a against L. major promastigotes
(EC50=35.0 μM) was much lower when compared with
its published activities against L. amazonensis (IC50=
0.6 μM) and L. braziliensis promastigotes (IC50=
0.8 μM).[7] Amphotericin B was applied as a proper
positive control for the tests with L. major parasites
despite of its severe side-effects.[11] In this study, the
toxicity of amphotericin B to Vero cells was distinctly
higher when compared with 1g and 1j, for example,
which did not harm Vero cells at doses of 100 μM and
still showed moderate activity against amastigotes.
Conclusions
A series of bis-naphthoquinone derivatives with
variance in the aryl residue at the bridging methylene
carbon were prepared and tested on various protozoal
parasites against which they showed distinctly differ-
ent activities. We identified compounds that were
remarkably active against T. gondii cells (e.g., the
fluorophenyl derivatives 1a and 1c, and the furan 1l),
and sufficiently selective for L. major amastigotes (e.g.,
the fluorophenyl derivative 1g and isovanillyl deriva-
tive 1j) to warrant further drug optimization studies. It
should be noted that in our tests with different
parasites we could not confirm the excellent activities
published for 1a.[7] Although this compound was
among the most active ones of this series, its toxic
Figure 1. Structures of target compounds 1a–1l.
Scheme 1. Synthesis of bis-naphthoquinone derivatives. Re-
agents and conditions: i) Aryl aldehyde (0.5 equiv.), cat. β-
alanine, AcOH, 50 °C, 2 h, 30–62%.
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effect on normal epithelial Vero cells is unfavorable for
an antiparasitic drug. It might hold, however, like the
new compound 1h, some potential as an antitumoral
drug candidate.
Experimental Section
General
All starting compounds were purchased from Aldrich.
The known compounds 1a and 1b were prepared
according to literature procedures.[7,12] The following
instruments were used: melting points (uncorrected),
Gallenkamp; IR spectra, PerkinElmer Spectrum One FT-
Table 1. Effective concentrations EC50 of compounds 1a–1l when applied to cells of Toxoplasma gondii and their inhibitory
concentrations IC50 when applied to Trypanosoma brucei brucei cells as well as IC50 values for Vero (African green monkey kidney
epithelial) cells.[a] Amphotericin B (AmB), pentamidine, and atovaquone (ATO) were applied as positive controls.
Compound IC50 (Vero, [μM]) EC50 (T. gondii, [μM]) SI (Vero/T. gondii)
[b] IC50 (T. b. brucei, [μM]) SI (Vero/T. b. brucei)
[c]
1a 6.78 11.64 0.58 15.6 0.43
1b 53.48 26.63 2.0 >10 –
1c 17.63 13.95 1.26 >10 –
1d 27.54 34.53 0.80 >100 –
1e 39.37 27.94 1.41 >10 –
1f 24.06 23.86 1.01 >10 –
1g 142.3 48.94 2.91 – –
1h 6.88 21.47 0.32 72.3 0.10
1i >100 109.0 – 27.8 >3.60
1j >100 59.28 – – –
1k 57.41 25.33 2.27 >100 –
1l 68.25 23.22 2.94 >10 –
AmB 7.7 – – – –
Pentamidine – – – 0.042[d] .
ATO 9.5 0.07 136 – –
[a] Values are the means of at least three independent experiments (SD �15%). They were derived from concentration–response
curves obtained by measuring the percentage of vital cells relative to untreated controls after 72 h. [b] Selectivity index (EC50/IC50)
calculated from the corresponding EC50 (T. gondii) and IC50 (Vero) values.
[c] Selectivity index calculated from the corresponding IC50
(T. b. brucei) and IC50 (Vero) values.
[d] Value is taken from ref. [8].
Table 2. Effective concentrations EC50 of compounds 1a–1l when applied to promastigotes and amastigotes of Leishmania
major.[a] Amphotericin B (AmB) was applied as positive control.
Compound EC50 (promastigotes, [μM]) EC50 (amastigotes, [μM]) SI (Vero/promastigotes)
[b] SI (Vero/amastigotes)[c]
1a 35.0 32.4 0.19 0.21
1b 116.0 48.0 0.46 1.12
1c 92.5 23.7 0.19 0.74
1d 89.1 77.2 0.31 0.36
1e 83.0 36.4 0.48 1.08
1f 76.5 22.6 0.32 1.06
1g 108 34.1 1.32 4.18
1h 35.5 30.1 0.19 0.23
1i >200 106.0 – >0.94
1j 97.4 37.9 >1.03 >2.64
1k 101 33.5 0.57 1.71
1l 94.1 53.7 1.27 0.73
AmB 0.83 0.47 9.6 16.4
[a] Values are the means of at least three independent experiments (SD �15%). They were derived from concentration  response
curves obtained by measuring the percentage of vital cells relative to untreated controls after 72 h. [b] Selectivity index (IC50/EC50)
calculated from the corresponding IC50 values for Vero cells and the EC50 values against L. major promastigotes.
[c] Selectivity index
calculated from the corresponding IC50 values for Vero cells and the EC50 values for L. major amastigotes.
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IR spectrophotometer with ATR sampling unit; nuclear
magnetic resonance spectra, Bruker Avance 300 spec-
trometer; chemical shifts are given in parts per million
(δ) downfield from tetramethylsilane as internal
standard; mass spectra, Varian MAT 311A (EI), Q
Exactive (ESI, HRMS, solutions of MeCN); microanalyses,
PerkinElmer 2400 CHN elemental analyzer. All tested
compounds are >95% pure by elemental analysis.
2,2’-[(4-Fluorophenyl)methylene]bis(3-hydroxy-
naphthalene-1,4-dione) (1a). Yield: 69 mg
(0.15 mmol, 30%). MS: 454 (21) [M+ ·], 436 (21), 408
(31), 252 (100), 224 (22), 196 (27), 174 (63), 105 (68), 76
(46).
2,2’-[(3-Fluorophenyl)methylene]bis(3-hydroxy-
naphthalene-1,4-dione) (1b). Yield: 68 mg
(0.15 mmol, 30%). MS: 454 (83) [M+ ·], 436 (57), 408
(84), 280 (33), 251 (100), 174 (70), 105 (87), 76 (56).
2,2’-[(3,4-Difluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1c) – General Proce-
dure. 2-Hydroxy-1,4-naphthoquinone (174 mg,
1.00 mmol), 3,4-difluorobenzaldehyde (71 mg,
0.5 mmol) and a catalytic amount of β-alanine (15 mg)
were dissolved in AcOH (8 mL). The reaction mixture
was stirred at 50 °C for 2 h. The reaction mixture was
poured on water (30 mL), the precipitate was collected
and dried in vacuum. Yield: 70 mg (0.15 mmol, 30%).
Yellow solid. M.p. 109–110 °C. ATR-IR: 3340, 1642,
1593, 1515, 1460, 1431, 1362, 1336, 1269, 1211, 1162,
1115, 1044, 1013, 977, 918, 887, 868, 816, 756, 723,
693. 1H-NMR (300 MHz, CDCl3): 6.10 (1 H. s), 7.0–7.2 (3
H, m), 7.6–7.8 (4 H, m), 8.0–8.1 (4 H, m). 13C-NMR
(75.5 MHz, CDCl3): 37.4 (CH), 110.7 (quinone-C3),
116.7–117.6 (m, fluoroaryl-C2, C5), 122.0 (fluoroaryl-
C6), 124.3, 126.4, 126.5, 126.7, 127.3, 129.4, 132.7,
133.3 (aryl-carbons), 135.3–135.6 (m, fluoroaryl-C1),
147.6 (fluoroaryl-C3), 154.3 (C  OH), 181.3 (CO), 184.1
(CO). MS: 472 (63) [M+ ·], 454 (55), 426 (72), 270 (100),
242 (22), 214 (36), 174 (86), 105 (86) 76 (52). HR-ESI-MS:
calc. for C27H15O6F2, [M+H]
+, 473.08312; found
473.08213.
2,2’-[(3,5-Difluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1d). Compound 1d
was prepared analogously to 1c from 2-hydroxy-1,4-
naphthoquinone (174 mg, 1.00 mmol), 3,5-difluoro-
benzaldehyde (71 mg, 0.5 mmol) and a catalytic
amount of β-alanine (15 mg) in AcOH (8 mL). Yield:
90 mg (0.21 mmol, 42%). Yellow solid. M.p. 116–
118 °C. ATR-IR: 3327, 1649, 1624, 1594, 1459, 1365,
1337, 1300, 1266, 1213, 1158, 1115, 1045, 990, 919,
853, 795, 725, 686. 1H-NMR (300 MHz, CDCl3): 6.14 (1 H,
s), 6.6–6.7 (1 H, m), 6.7–6.8 (2 H, m), 7.6–7.8 (4 H, m),
8.0–8.1 (4 H, m). 13C-NMR (75.5 MHz, CDCl3): 37.6 (CH),
101.8–102.5 (m, fluoroaryl-C4), 110.7 (quinone-C3),
111.1–111.5 (m, fluoroaryl-C2, C6), 121.4, 126.4, 126.7,
127.3, 129.4, 132.7, 133.1, 133.3, 135.3 (aryl carbons),
142.7–142.9 (m, fluoroaryl-C1), 154.5 (C  OH), 161.2–
164.6 (m, fluoroaryl-C3, C5), 181.3 (CO), 184.0 (CO). MS:
472 (92) [M+ ·], 454 (69), 426 (100), 382 (23), 359 (29),
326 (18), 298 (31), 269 (31), 214 (23), 105 (62), 104 (61),
76 (38). HR-ESI-MS: calc. for C27H15O6F2, [M+H]
+,
473.08312; found 473.08267.
2,2’-[(2,4-Difluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1e). Compound 1e
was prepared analogously to 1c from 2-hydroxy-1,4-
naphthoquinone (174 mg, 1.00 mmol), 2,4-difluoro-
benzaldehyde (71 mg, 0.5 mmol) and a catalytic
amount of β-alanine (15 mg) in AcOH (8 mL). Yield:
138 mg (0.29 mmol, 58%). Yellow solid. M.p. 169–
170 °C. ATR-IR: 3336, 1647, 1593, 1502, 1461, 1428,
1364, 1338, 1297, 1274, 1258, 1211, 1161, 1139, 1090,
1044, 1012, 967, 938, 903, 848, 816, 798, 782, 722, 693,
679, 646, 608. 1H-NMR (300 MHz, CDCl3): 6.23 (1 H, s),
6.7–6.8 (2 H, m), 7.1–7.2 (1 H, m), 7.6–7.8 (4 H, m),
8.0–8.1 (4 H, m). 13C-NMR (75.5 MHz, CDCl3): 32.1 (CH),
103.1–103.6 (m, fluoroaryl-C3), 110.5–110.8 (m, fluo-
roaryl-C5, quinone-C3), 121.3, 126.3, 127.2, 129.3,
130.2–130.5 (m), 132.8, 133.1, 135.2 (aryl carbons),
154.0 (C  OH), 161.0–164.0 (m, fluoroaryl-C2, C4), 181.3
(CO), 183.8 (CO). MS: 472 (4) [M+ ·], 452 (100), 426 (53),
279 (27), 251 (32), 174 (26), 105 (60), 76 (48). HR-ESI-
MS: calc. for C27H15O6F2, [M+H]
+, 473.08312; found
473.08247.
2,2’-[(2,4,5-Trifluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1f). Compound 1f was
prepared analogously to 1c from 2-hydroxy-1,4-naph-
thoquinone (174 mg, 1.00 mmol), 2,4,5-trifluorobenzal-
dehyde (80 mg, 0.5 mmol) and a catalytic amount of
β-alanine (15 mg) in AcOH (8 mL). Yield: 130 mg
(0.27 mmol, 54%). Yellow solid. M.p. 167–169 °C. ATR-
IR: 3347, 1647, 1593, 1513, 1461, 1424, 1364, 1334,
1276, 1261, 1212, 1188, 1151, 1098, 1043, 1011, 970,
938, 911, 870,3 840, 816, 796, 762, 723, 688, 658, 638.
1H-NMR (300 MHz, CDCl3): 6.20 (1 H, s), 6.8–6.9 (1 H,
m), 7.0–7.1 (1 H, m), 7.6–7.8 (4 H, m), 8.0–8.1 (4 H, m).
13C-NMR (75.5 MHz, CDCl3): 32.0 (CH), 104.9–105.3 (m,
fluoroaryl-C3), 117.8–118.1 (m, fluoroaryl-C6), 120.7
(fluoroaryl-C6), 126.4, 127.3, 129.2, 132.8, 133.2, 135.3
(aryl carbons), 148.0 (fluoroaryl-C5), 151.0 (fluoroaryl-
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C4), 153.9 (C  OH), 157.5 (fluoroaryl-C2), 181.2 (CO),
183.6 (CO). MS: 490 (9) [M+ ·], 470 (100), 444 (76), 298
(37), 288 (31), 269 (47), 104 (72), 76 (54). HR-ESI-MS:
calc. for C27H14O6F3, [M+H]
+, 491.07370; found:
491.07311.
2,2’-[(3,4,5-Trifluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1g). Compound 1f
was prepared analogously to 1c from 2-hydroxy-1,4-
naphthoquinone (174 mg, 1.00 mmol), 3,4,5-trifluoro-
benzaldehyde (80 mg, 0.5 mmol) and a catalytic
amount of β-alanine (15 mg) in AcOH (8 mL). Yield:
120 mg (0.25 mmol, 50%). Yellow solid. M.p. 116–
117 °C. ATR-IR: 3318, 1647, 1620, 1593, 1527, 1460,
1444, 1363, 1338, 1260, 1213, 1159, 1040, 998, 971,
919, 879, 868, 852, 817, 797, 725, 700. 1H-NMR
(300 MHz, CDCl3): 6.08 (1 H, s), 6.9–7.0 (2 H, m), 7.7–
7.8 (4 H, m), 8.1–8.2 (4 H, m). 13C-NMR (75.5 MHz,
CDCl3): 37.5 (CH), 110.7 (quinone-C3), 112.4–112.7 (m,
fluoroaryl-C2, C6), 121.3, 126.4, 126.5, 126.7, 127.3,
129.3, 132.7, 133.1, 133.3, 135.3 (aryl carbons), 148.9
(fluoroaryl-C4), 152.5 (fluoroaryl-C3, C5), 154.3 (C  OH),
181.3 (CO), 183.9 (CO). MS: 490 (62) [M+ ·], 472 (51),
444 (100), 416 (11), 400 (14), 359 (27), 344 (12), 288
(26), 232 (14), 174 (20), 147 (12), 104 (38), 76 (21). HR-
ESI-MS: calc. for C27H14O6F3, [M+H]
+, 491.07370;
found: 491.07262.
2,2’-[(Pentafluorophenyl)methylene]bis(3-hy-
droxynaphthalene-1,4-dione) (1h). Compound 1h
was prepared analogously to 1c from 2-hydroxy-1,4-
naphthoquinone (174 mg, 1.00 mmol), pentafluoro-
benzaldehyde (98 mg, 0.5 mmol) and a catalytic
amount of β-alanine (15 mg) in AcOH (6 mL). Yield:
160 mg (0.30 mmol, 61%). Yellow solid. M.p. 110–
111 °C. ATR-IR: 3327, 1648, 1594, 1522, 1499, 1364,
1339, 1275, 1213, 1117, 1045, 999, 977, 911, 785, 724,
699. 1H-NMR (300 MHz, CDCl3): 6.17 (1 H, s), 7.59 (2 H,
s), 7.6–7.8 (4 H, m), 8.0–8.1 (4 H, m). 13C-NMR
(75.5 MHz, CDCl3): 29.1 (CH), 113.8–114.2 (m, fluoroar-
yl-C1), 119.7, 126.4, 126.9, 127.2, 129.2, 132.7, 133.2,
135.4 (aryl carbons), 137.8–139.2 (m, fluoroaryl-C3,
C5), 141.5–142.2 (m, fluoroaryl-C2, C6), 143.7–144.6
(m, fluoroaryl-C2, C6), 147.1–148.6 (m, fluoroaryl-C4),
153.4 (C  OH), 181.1 (CO), 183.4 (CO). MS: 526 (79) [M+
·], 506 (66), 480 (100) 434 (20), 359 (36), 334 (64), 305
(51), 174 (38), 105 (78), 104 (79), 76 (47). HR-ESI-MS:
calc. for C27H12O6F5, [M+H]
+, 527.05486; found
527.05347.
2,2’-[(4-Hydroxy-3-methoxyphenyl)methylene]
bis(3-hydroxynaphthalene-1,4-dione) (1i). Com-
pound 1i was prepared analogously to 1c from 2-
hydroxy-1,4-naphthoquinone (174 mg, 1.00 mmol), va-
nillin (76 mg, 0.5 mmol) and a catalytic amount of β-
alanine (15 mg) in AcOH (6 mL). Yield: 80 mg
(0.17 mmol, 34%). Yellow solid. M.p. 107–108 °C. ATR-
IR: 3294, 1645, 1592, 1580, 1513, 1460, 1431, 1362,
1336, 1252, 1206, 1155, 1122, 1030, 972, 915, 867, 813,
796, 722. 1H-NMR (300 MHz, CDCl3): 3.79 (3 H, s), 5.52
(1 H, s), 6.7–6.8 (3 H, m), 7.6–7.8 (4 H, m), 7.9–8.1 (6 H,
m). 13C-NMR (75.5 MHz, CDCl3): 37.6 (CH), 56.0 (MeO),
110.7 (quinone-C3), 111.3 (phenyl-C2), 114.1 (phenyl-
C5), 121.1 (phenyl-C6), 122.9, 126.3, 126.5, 127.2, 129.6,
132.8, 133.2, 135.1 (aryl carbons), 144.6 (phenyl-C4),
146.5 (phenyl-C3), 154.5 (quinone-C  OH), 181.4 (CO),
184.6 (CO). MS: 482 (8) [M+ ·], 464 (5), 308 (45), 280
(100), 263 (14), 249 (27), 237 (19), 209 (12), 174 (73),
146 (16), 105 (64), 76 (27). HR-ESI-MS: calc. for
C28H19O8, [M+H]
+, 483.10744; found 483.10624.
2,2’-[(3-Hydroxy-4-methoxyphenyl)methylene]-
bis(3-hydroxynaphthalene-1,4-dione) (1j). Com-
pound 1j was prepared analogously to 1c from 2-
hydroxy-1,4-naphthoquinone (174 mg, 1.00 mmol),
isovanillin (76 mg, 0.5 mmol) and a catalytic amount of
β-alanine (15 mg) in AcOH (6 mL). Yield: 80 mg
(0.17 mmol, 34%). Yellow solid. M.p. 114–116 °C. ATR-
IR: 3334, 1646, 1592, 1579, 1510, 1460, 1441, 1362,
1336, 1259, 1211, 1128, 1045, 1023, 981, 916, 885, 868,
798, 740, 723, 692, 656. 1H-NMR (300 MHz, CDCl3): 3.83
(3 H, s), 5.53 (1 H, s), 6.14 (1 H, s), 6.3–6.4 (3 H, m), 7.6–
7.8 (4 H, m), 8.0–8.1 (4 H, m). 13C-NMR (75.5 MHz,
CDCl3): 37.0 (CH), 55.9 (MeO), 110.4 (quinone-C3),
114.6 (phenyl-C5), 119.6 (phenyl-C2), 122.7 (phenyl-
C6), 126.3, 126.5, 127.2, 129.6, 131.0, 132.7, 133.2,
135.0 (aryl carbons), 145.5 (phenyl-C4), 154.8 (quinone-
C  OH), 181.3 (CO), 184.7 (CO). MS: 482 (5) [M+ ·], 308
(47), 280 (100), 265 (22), 249 (27), 237 (25), 209 (17),
174 (87), 146 (23), 105 (97), 76 (42). HR-ESI-MS: calc. for
C28H19O8, [M+H]
+, 483.10744; found 483.10706.
2,2’-[(Furan-2-yl)methylene]bis(3-hydroxynaph-
thalene-1,4-dione) (1k). Compound 1k was prepared
analogously to 1c from 2-hydroxy-1,4-naphthoquinone
(174 mg, 1.00 mmol), furfural (57 mg, 0.5 mmol) and a
catalytic amount of β-alanine (15 mg) in AcOH (6 mL).
Yield: 80 mg (0.19 mmol, 38%). Yellow solid. M.p. 118–
120 °C. ATR-IR: 3329, 1647, 1592, 1580, 1501, 1460,
1363, 1336, 1261, 1212, 1160, 1142, 1092, 1074, 1043,
1011, 970, 883, 869, 819, 797, 761, 722. 1H-NMR
(300 MHz, CDCl3): 6.09 (1 H, d, J=3.3), 6.20 (1 H, s),
6.2–6.3 (1 H, m), 7.3–7.4 (1 H, m), 7.6–7.8 (4 H, m),
8.0–8.1 (4 H, m), 8.2–8.3 (2 H, br. s). 13C-NMR
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(75.5 MHz, CDCl3): 31.8 (CH), 107.2 (furyl-C3), 110.5
(quinone-C3), 120.7, 126.4, 127.2, 129.6, 132.6, 133.3,
135.0 (aryl carbons), 141.8 (furyl-C5), 150.5 (furyl-C2),
154.8 (C  OH), 181.2 (CO), 184.3 (CO). MS: 426 (43) [M+
·], 224 (42), 174 (100), 146 (22), 105 (78), 77 (23). HR-
ESI-MS: calc. for C25H15O7, [M+H]
+, 427.08123; found
427.08009.
2,2’-[(Furan-3-yl)methylene]bis(3-hydroxynaph-
thalene-1,4-dione) (1l). Compound 1l was prepared
analogously to 1c from 2-hydroxy-1,4-naphthoquinone
(174 mg, 1.00 mmol), furyl-3-aldehyde (57 mg,
0.5 mmol) and a catalytic amount of β-alanine (15 mg)
in AcOH (6 mL). Yield: 100 mg (0.24 mmol, 48%).
Yellow solid. M.p. 167–170 °C. ATR-IR: 3328, 1646,
1592, 1579, 1502, 1460, 1362, 1336, 1264, 1219, 1158,
1071, 1044, 1024, 967, 920, 891, 872, 793, 756, 739,
722, 682, 658. 1H-NMR (300 MHz, CDCl3): 6.0–6.1 (1 H,
m), 6.3–6.4 (1 H, m), 7.3–7.4 (1 H, m), 7.6–7.8 (4 H, m),
8.0–8.1 (4 H, m). 13C-NMR (75.5 MHz, CDCl3): 28.9 (CH),
111.5 (quinone-C3), 121.9, 122.2, 126.4, 127.1, 129.6,
132.6, 133.3, 135.0 (aryl carbons), 140.2 (furyl-C2),
143.0 (furyl-C5), 154.9 (C  OH), 181.2 (CO), 184.8 (CO).
MS: 426 (14) [M+ ·], 252 (21), 224 (66), 196 (57), 174
(100), 146 (24), 139 (27), 105 (96), 76 (42). HR-ESI-MS:
calc. for C25H15O7, [M+H]
+, 427.08123; found
427.08056.
Toxoplasma gondii Culture Conditions
Serial passages of the cell lines Vero (ATCC® CCL81™,
USA) were used for the cultivation of T. gondii
tachyzoites of the RH strains (a gift from Dr. Saeed El-
Ashram, State Key Laboratory for Agrobiotechnology,
China Agricultural University, Beijing, China). Vero cells
were cultured by using RPMI 1640 medium (Sigma,
USA) with heat-inactivated 10% fetal bovine serum
(FBS, Invitrogen, USA) in a humidified 5% CO2
atmosphere at 37 °C. 96-Well plates (5×103 cells/well
in 200 μL RPMI 1640 medium) were used for the
cultivation of the Vero cells and then incubated at
37 °C and 5% CO2 for one day, followed by removal of
medium and washing the cells with phosphate
buffered saline (PBS). Then, RPMI 1640 medium with
2% FBS containing tachyzoites (RH strains) of T. gondii
at a ratio of 5 (parasite): 1 (Vero cells) was added. After
incubation at 37 °C and 5% CO2 for 5 h, cells were
washed with PBS and then overlaid with medium
containing tested compounds or atovaquone (50, 25,
12.5, 6.25, 3.13, 1.65, and 0.75 μgmL  1).
After incubation at 37 °C and 5% CO2 for 72 h, the
cells were stained with 1% toluidine blue after
washing with PBS and fixation in 10% formalin. The
cells were examined under an inverted photomicro-
scope (MCD-400, Leica, Japan) to determine the
infection index (number of infected cells from 200
tested cells) of T. gondii.[13,14]
Leishmania major Promastigotes and Amastigotes
Promastigotes of L. major were isolated from a Saudi
male patient in February 2016 and maintained at 26 °C
in Schneider’s Drosophila medium (Invitrogen, USA)
supplemented with 10% heat inactivated FBS (Invitro-
gen, USA) and antibiotics in a tissue culture flask with
weekly transfers. Promastigotes were cryopreserved in
liquid nitrogen at concentrations of 3×106 parasite/ml.
The virulence of L. major parasites was maintained by
passing in female BALB/c mice by injecting hind
footpads with 1×106 stationary-phase promastigotes.
After 8 weeks, L. major amastigotes were isolated from
mice. Isolated amastigotes were transformed to pro-
mastigote forms by culturing at 26 °C in Schneider’s
medium supplemented with 10% FBS and antibiotics.
For infection, amastigote-derived promastigotes with
less than five in vitro passages were used. Male and
female BALB/c mice were obtained from Pharmaceut-
ical College, King Saud University, Kingdom of Saudi
Arabia, and maintained in specific pathogen-free
facilities.
In order to evaluate the activity of tested com-
pounds against L. major promastigotes, promastigotes
from logarithmic-phase cultured in phenol red-free
RPMI 1640 medium (Invitrogen, USA) with 10% FBS
were suspended on 96-wells plates to yield 106 cells
mL  1 (200 μL/well) after hemocytometer counting.
Compounds were added to obtain the final concen-
trations (50, 25, 12.5, 6.25, 3.13, 1.65, and
0.75 μgmL  1). Negative control wells containing cul-
tures with DMSO (1%) and without compound and
positive control wells containing cultures with decreas-
ing concentration of amphotericin B (reference com-
pound, 50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 μgmL  1)
were used. Plates were incubated at 26 °C for 72 h to
evaluate the antiproliferative effect. The number of
viable promastigotes were assessed by colorimetric
method using the tetrazolium salt colorimetric assay
(MTT). It measures the reduction of the MTT compo-
nent into an insoluble formazan product. This colored
product was solubilized by adding detergent solution
to lyse the cells. The samples were analyzed by using a
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microplate absorbance spectrophotometer (xMark,
Bio-Rad, USA) at 570 nm.[14]
In order to evaluate the activity of tested com-
pounds against amastigotes in macrophages, perito-
neal macrophages from female BALB/c mice (6–8
weeks of age) were collected by aspiration, then 5×
104 cells/well were seeded on 96-wells plates in RPMI
1640 medium with 10% FBS for 4 h at 37 °C in 5% CO2
atmosphere to promote cell adhesion. Medium was
discarded and washed with PBS. 200 μL of solution
containing L. major promastigotes (at a ratio of 10
promastigotes: 1 macrophage in RPMI 1640 medium
with 10% FBS) were added per well. Plates were
incubated for 24 h at 37 °C in humidified 5% CO2
atmosphere to allow infection and amastigote differ-
entiation. Then, the infected macrophages were
washed three times with PBS to remove the free
promastigotes and overlaid with fresh RPMI 1640
medium containing compounds at final concentrations
(50, 25, 12.5, 6.25, 3.13, 1.65, and 0.75 μgmL  1) and
cells were incubated at 37 °C in humidified 5% CO2
atmosphere for 72 h. Negative control containing
cultures with DMSO (1%) and without compounds
and positive control wells containing cultures with
decreasing concentration of amphotericin B (reference
compound, 50, 25, 12.5, 6.25, 3.13, 1.65, and
0.75 μgmL  1) were used. The percentage of infected
macrophages was evaluated microscopically after
removing medium, washing, fixation, Giemsa
staining.[14]
Trypanosoma Cell Line and Culture Conditions
Cells of the T. b. brucei bloodstream trypomastigote
cell lines Lister 427 were maintained in HMI-9 medium,
pH 7.5, supplemented with 10% FBS in a humidified
5% CO2 atmosphere at 37 °C.[15]
Alamar Blue (AB) Assay
The AB assay was used to identify viable cells after
treatment with drug candidates.[16–19] This assay was
based on the irreversible reaction of the blue dye
resazurin and NADH to pink resofurin in intact cells. T.
b. brucei cells (8000/well) were seeded on 96-well
microplates, treated with the tested compounds
(dissolved in DMSO) and incubated for 72 h (5% CO2,
95% humidity, 37 °C). 10 μL of the AB reagent (500 mM
resazurin sodium salt in PBS) were added and
incubated for further 4 h at 37 °C. The fluorescence
(extinction at 544 nm, emission at 590 nm) was
measured on an Omega Fluostar (BMG Labtech)
fluorescence plate reader.
Cytotoxicity Assay
MTT assay was carried out for cytotoxicity evaluation
of compounds. Briefly, Vero cells were cultured in 96-
well plates (5×103 cells/well/200 μL) for 24 h in RPMI
1640 medium with 10% FBS and 5% CO2 at 37 °C.
Cells were washed with PBS and treated with tested
compounds for 72 h at varying concentrations (50, 25,
12.5, 6.25, 3.13, 1.65, and 0.75 μgmL  1) in medium
with 10% FBS. As negative control, cells were treated
with medium only. Thereafter, the supernatant was
removed and 50 μL RPMI 1640 medium containing
14 μL MTT (5 mgmL  1) were added and incubated for
4 h. After that, the supernatant was removed and
150 μL DMSO were added in order to dissolve the
formazan. Microplate absorbance spectrophotometer
was applied for colorimetric analysis (λ=540 nm).
Cytotoxic effects were expressed by IC50 values
(concentration that caused a 50% reduction in viable
cells).[14,20]
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